Cardiology

Endocrinology

Questions discussed in this category

How many days prior to surgery do you recommend stopping SGLT2 inhibitors and when is it safe to resume therapy?

Would you consider using Evenity in an elderly patient with rate controlled atrial fibrillation without history of MI or CVA?

1 Answer available

Would you consider adding niacin to the lipid lowering regimen in statin-intolerant patients who cannot afford PCSK9i or bempedoic acid?

Ferrell et al., PMID 38448791

5 Answers available

Do you recommend adding low-dose Aspirin for primary prevention in patients with Type 2 Diabetes on Eliquis for another indication?

1 Answer available

Does oral semaglutide provide similar cardiovascular risk reduction benefits as injectable semaglutide?

1 Answer available

Should all kidney transplant patients be started on statin therapy post operatively given their increased risk of CVD?

At what doses do you start? and how do you titrate therapy?

1 Answer available

In ischemic stroke patients with low LDL levels (<30-50 mg/dl), would you consider lowering LDL levels to lower values without concern for any side effects?

How would you adjust statin therapy in these patients?

3 Answers available

Are recurrent UTIs a contraindication to SGLT2i use?

4 Answers available

Should low-intensity statins be favored to minimize the risk of diabetes onset while still offering cardiovascular benefit for patients with prediabetes where a statin is indicated?

Cholesterol Treatment Trialists' (CTT) Collaboration

2 Answers available

Should we recommend SGLT2i initiation at discharge to all patients hospitalized with acute myocardial infarction?

Butler et al., PMID 38587237

1 Answer available

Is ABI (Ankle Brachial index) lower limb arterial doppler not recommended if patient already has arterial stents in the legs, and if so, what other imaging modality would you consider as first-line?

1 Answer available

When and for whom should we consider adding bempedoic acid to the lipid lowering regimen?

3 Answers available

How do you counsel patients with non-statin associated inflammatory myopathies about statin use?

1 Answer available

Is there enough evidence now to use injectable semaglutide as a foundational therapy for symptomatic heart failure with preserved ejection fraction in the setting of overweight or obesity?

1 Answer available

Do you recommend continuing SGLT2 inhibitors in patients with diabetic kidney disease and congestive heart failure who have been taking the medication for several years and later develop end stage kidney disease?

3 Answers available

Should a toe-brachial index be obtained in lieu of resting ABI as an initial screen for PAD in high-risk patients such as those with longstanding diabetes or advanced age with stiffened vessels?

1 Answer available

Do you change management in patients that are taking bisphosphonates and develop atrial fibrillation?

1 Answer available

Papers discussed in this category

The New England journal of medicine, 2015 Sep 17

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

The New England journal of medicine, 2020 Sep 24

Dapagliflozin in Patients with Chronic Kidney Disease.

The New England journal of medicine, 2023 Aug 25

Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.

Curr Rheumatol Rep, 2020 Aug 26

Lipid-lowering Therapies in Myositis.

The New England journal of medicine, 2024 Apr 06

Empagliflozin after Acute Myocardial Infarction.

The American journal of cardiology, 2004-02-01

Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (The HDL Atherosclerosis Treatment Study).

Nature medicine, 2024 Feb 19

A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk.

Journal of clinical lipidology, 2024 Mar 29

A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice.

Stroke, 2007-12

Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.

The New England journal of medicine, 2006 Aug 10

High-dose atorvastatin after stroke or transient ischemic attack.

European heart journal, 2020 Jan 01

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.

Journal of the American Heart Association, 2023 Sep 08

Statin Treatment in Patients With Stroke With Low-Density Lipoprotein Cholesterol Levels Below 70 mg/dL.

Circulation, 2019-06-18

2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

The New England journal of medicine, 2016 Sep 15

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

Cardiology

Endocrinology

Questions discussed in this category

Papers discussed in this category

Related Topics in Cardiology